Treatment strategy for colorectal cancer with resectable synchronous liver metastases: Is any evidence-based strategy possible?

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 4, Issue 8

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

300

HTML

2580

Tables (1-2)

134

Sum=3014

Aug 27, 2012 (publication date) through Apr 28, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial

World J Hepatol. Aug 27, 2012; 4(8): 237-241
Published online Aug 27, 2012. doi: 10.4254/wjh.v4.i8.237

Table 2 Outcome of “Up-front chemotherapy” strategy: risk of emergency surgery while on treatment n (%)

Author	Year	Patients	Resectable at diagnosis	Oxaliplatin- or Irinotecan-based chemotherapy (%)	Emergency surgery
Benoist et al[37]	2005	27	No	67	4 (14.8)
Muratore et al[38]	2007	35	No	100	1 (2.8)
Poultsides et al[39]	2009	233	No	100	16 (7)
Karoui et al[40]	2011	123	No	90	15 (12.1)
Viganò/Capussotti¹	2012	40	Yes	100	3 (7.5)

¹Unpublished data.

Citation: Viganò L. Treatment strategy for colorectal cancer with resectable synchronous liver metastases: Is any evidence-based strategy possible? World J Hepatol 2012; 4(8): 237-241
URL: https://www.wjgnet.com/1948-5182/full/v4/i8/237.htm
DOI: https://dx.doi.org/10.4254/wjh.v4.i8.237